Loading the section…
The price of Neuphoria Therapeutics Inc. (NEUP) on October 9, 2026 is 3.36 USD, +0.30% on the day. Over 52 weeks the stock traded between 3.19 USD and 19.21 USD; the price now sits 1% of the way up that range. Over the past year the price changed by −81.71%. Market capitalization is 5.84 million USD, rank 321 among 373 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
Change over the period shown (line colour): −79.90 %
Neuphoria Therapeutics Inc. trades on Nasdaq under the ticker NEUP. The company belongs to the Health care sector. The trading history on this page starts on 16 December 2021.
Over the past 52 weeks NEUP has traded between 3.19 $ and 19.21 $. As of 9 October 2026 the price stood 1.06 % of the way from the 52-week low to the high.
Over one year NEUP shares fell 81.71 %; over six months they fell 29.71 %. Volatility over 90 days is 56.77 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 0.4, below the sector median of 4.0. Price to book is 0.2, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 3.33 | 3.41 | 3.32 | 3.36 | 2,500 |
| 8 October 2026 | 3.40 | 3.42 | 3.34 | 3.35 | 16,500 |
| 7 October 2026 | 3.40 | 3.45 | 3.40 | 3.42 | 4,500 |
| 6 October 2026 | 3.45 | 3.50 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
No events for this security recently.
Address:100 SUMMIT DR, BURLINGTON, MA, 01803, US
Neuphoria Therapeutics Inc. reported revenue of 16M $ and a net loss of 17M $ over the last four quarters. Earnings per share are −6.09 $. Market capitalisation is 6M $.
NEUP has a return on equity of −59.34 %, below the sector median of −41.68 %. Return on assets is −50.16 %, below the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 3.43 |
| 3.45 |
| 16,500 |
| 5 October 2026 | 3.45 | 3.50 | 3.43 | 3.45 | 15,500 |
| 2 October 2026 | 3.51 | 3.59 | 3.45 | 3.47 | 12,600 |
| 1 October 2026 | 3.53 | 3.54 | 3.50 | 3.51 | 14,300 |
| 30 September 2026 | 3.60 | 3.62 | 3.53 | 3.56 | 10,400 |
| 29 September 2026 | 3.64 | 3.65 | 3.57 | 3.57 | 15,000 |
| 28 September 2026 | 3.67 | 3.69 | 3.65 | 3.65 | 2,900 |
| 25 September 2026 | 3.67 | 3.67 | 3.65 | 3.65 | 1,300 |
| 24 September 2026 | 3.67 | 3.70 | 3.65 | 3.65 | 5,400 |
| 23 September 2026 | 3.69 | 3.76 | 3.66 | 3.68 | 15,500 |
| 22 September 2026 | 3.73 | 3.77 | 3.71 | 3.74 | 6,700 |
| 21 September 2026 | 3.69 | 3.79 | 3.68 | 3.71 | 17,900 |
| 18 September 2026 | 3.71 | 3.83 | 3.70 | 3.70 | 21,600 |
| 17 September 2026 | 3.79 | 3.79 | 3.71 | 3.72 | 5,300 |
| 16 September 2026 | 3.72 | 3.81 | 3.72 | 3.74 | 36,800 |
| 15 September 2026 | 3.75 | 3.80 | 3.73 | 3.78 | 17,700 |
| 14 September 2026 | 3.78 | 3.84 | 3.74 | 3.80 | 12,400 |